Welcome to our dedicated page for Bioventus SEC filings (Ticker: BVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bioventus Inc. (BVS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered summaries to help interpret key points. As a Nasdaq Global Select Market issuer of Class A common stock, Bioventus files current reports on Form 8-K and other periodic reports that provide insight into its operations, governance and capital structure.
In its Form 8-K filings, Bioventus reports material events such as quarterly and year-to-date financial results, including net sales by business (Pain Treatments, Surgical Solutions and Restorative Therapies), net income and the use of non-GAAP measures like Adjusted EBITDA and non-GAAP earnings. These filings often reference accompanying press releases furnished as exhibits, which our AI tools can summarize to highlight segment performance and notable drivers.
Bioventus also uses Form 8-K to disclose financing arrangements, such as the 2025 Credit Agreement that established a $300 million term loan facility and a $100 million revolving credit facility. The filing details interest rate terms, leverage and coverage covenants, maturity dates and the use of proceeds to refinance prior credit facilities. AI analysis can help readers quickly understand how such agreements affect liquidity, leverage and future obligations.
Additional 8-K items cover governance changes, including the appointment of new directors under the terms of a Stockholders Agreement with certain major stockholders. These disclosures explain board composition, designation rights and whether directors receive compensation from the company.
On this page, users can access Bioventus 10-K annual reports, 10-Q quarterly reports, 8-K current reports and Form 4 insider transaction filings as they become available from EDGAR. Real-time updates and AI-generated explanations are designed to make complex filings more accessible, whether you are reviewing segment disclosures, credit facility terms or board changes related to BVS.
Bioventus files a comprehensive annual report describing its business, product portfolio, regulatory environment and principal risks. The company reports U.S. and International segments representing 88% and 12% of net sales for the year ended December 31, 2025, and lists core areas: Pain Treatments, Surgical Solutions and Restorative Therapies. The filing notes FDA 510(k) clearances for TalisMann and StimTrial in July 2025 and a limited commercial release in Q3 2025, followed by a broader launch in early 2026. It discloses intellectual property counts, manufacturing and supply constraints, key regulatory frameworks (U.S. FDA, EU MDR), material legal and reimbursement risks, and that the company had approximately 930 employees as of December 31, 2025.
Bioventus Inc. is asking stockholders to vote at its 2026 virtual Annual Meeting on June 3, 2026 at 10:00 a.m. Eastern Time. Holders of 67,638,295 shares of Class A and 15,786,737 shares of Class B common stock as of April 6, 2026 may vote, with each share receiving one vote.
Stockholders will elect twelve directors to one-year terms and vote on ratifying Grant Thornton LLP as independent auditor for 2026. The proxy details board and committee composition, director independence, governance policies, a Dodd-Frank–aligned compensation clawback, and sizeable equity incentive and employee stock purchase plans supporting long-term equity-based compensation.
Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.
Bioventus Inc. filed an amended insider report for director Philip G. Cowdy to correct a previously reported grant of 2,700 Restricted Stock Units dated April 1, 2021. A footnote explains the earlier Form 4 was filed inadvertently for RSUs that were not accepted, and that as of April 1, 2021, Cowdy held no non-derivative or derivative securities of Bioventus.
Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.
Bioventus Inc. director Philip G. Cowdy filed an amended insider report to correct a previously reported equity grant. A prior Form 4 had shown a grant of 9,000 restricted stock units, but the footnote explains this grant was not accepted. As of February 11, 2021, he held no non-derivative or derivative securities of Bioventus.
Bioventus Inc. senior vice president and CFO Mark Leonard Singleton reported routine equity compensation activity involving Class A common stock and restricted stock units. On April 10, 2026, he exercised 13,000 restricted stock units, receiving an equal number of Class A shares at a conversion price of $0.00 per share.
To cover related tax obligations, 5,648 Class A shares were disposed of through a tax-withholding transaction at $9.06 per share, a non‑market “F” code event rather than an open‑market sale. After these transactions, Singleton directly owned 182,981 Class A shares, reflecting a net increase in his equity position from this vesting and withholding sequence.
Bioventus Inc. executive Katrina J. Church, SVP & Chief Compliance Officer, exercised restricted stock units on April 10, 2026, receiving 4,300 shares of Class A common stock at a conversion price of $0.00 per share. Of these, 1,868 shares of Class A common stock were withheld at $9.06 per share to satisfy tax obligations, a non-market tax-withholding disposition. After these transactions, she directly owned 64,164 shares of Class A common stock. The footnotes explain that each RSU represents a right to receive one share of Class A common stock and that the RSUs vest in four equal installments on each of the first four anniversaries of April 10, 2023, subject to continued service.
Bioventus Inc. SVP & General Counsel Anthony D'Adamio exercised restricted stock units into shares of Class A common stock. On April 10, 2026, he converted 9,925 RSUs into 9,925 shares of Class A common stock at a conversion price of $0.00 per share.
To cover tax obligations related to this equity compensation, 4,312 shares of Class A common stock were disposed of at $9.06 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, he directly holds 153,655 shares of Class A common stock.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported routine equity compensation activity in the form of restricted stock units. On March 20, 2026, he exercised 18,625 RSUs, receiving the same number of shares of Class A common stock at a stated price of $0.00 per share.
To cover tax obligations related to this vesting, 8,091 shares of Class A common stock were withheld at $8.64 per share, classified as a tax-withholding disposition rather than an open-market sale. After these transactions, Singleton directly held 169,981 shares of Class A common stock.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported multiple equity compensation transactions in company stock. He received 104,000 restricted stock units and a stock option for 116,000 shares of Class A common stock at an exercise price of $8.6200 per share, both granted on March 13, 2026. He also reported earlier grants from March 14, 2025 of 54,000 RSUs and a stock option for 61,000 shares at $9.6100 per share. On the same 2026 date, he exercised 13,500 RSUs into 13,500 shares of Class A common stock, with 5,865 shares withheld to cover tax obligations. After these transactions, he directly holds 159,447 shares of Class A common stock. The RSUs and options vest in four equal annual installments starting on March 15, 2025 and March 15, 2026, subject to his continued service.
Bioventus Inc. senior vice president and chief compliance officer Katrina J. Church received new equity awards and exercised existing awards. On March 13, 2026 she was granted 24,000 restricted stock units and 27,000 stock options with an exercise price of $8.62 per share, all vesting in four annual installments starting March 15, 2026, subject to continued service.
Church also exercised a total of 6,955 restricted stock units into Class A common stock, with 3,022 shares withheld to cover tax obligations. After these transactions she directly holds 61,732 shares of Class A common stock, plus outstanding RSU and option awards disclosed in the filing.